Company Press Releases Back
CytoSorbents To Present at Biotech Showcase 2016
Monday January 4, 2016
MONMOUTH JUNCTION, N.J., Jan. 4, 2016 - CytoSorbents Corporation (CTSO) announced that Dr. Phillip Chan, MD, PhD, Chief Executive Officer, will present at the Biotech Showcase™ 2016 conference on Monday, January 11, 2016 in San Francisco, CA. The presentation will take place at 9:00 AM PST in Room Mission I of the Parc 55 San Francisco Hotel. Dr. Chan will provide an overview and update on the Company's current status and plans for 2016. He will be joined by Kathleen Bloch, Chief Financial Officer, and Chris Cramer, Vice President of Business Development during the informal question and answer session that will follow.
CytoSorbents' management will host one-on-one meetings at the conference. To meet with the Company, please contact Joseph Green at email@example.com to schedule a meeting. Currently, due to other meetings, the Company's schedule between January 11-13, 2016 is very limited.
About Biotech Showcase™
Biotech Showcase™ 2016 is one of the industry's largest annual healthcare investor and partnering conferences, with more than 225 company presentations and 2,100 attendees expected. Attendees include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The conference is run concurrently with, but independently from, the JP Morgan Healthcare Conference in San Francisco, one of the largest and most influential international healthcare conferences.
Now in its eighth year, the Biotech Showcase™ features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a commercial-stage, critical care focused immunotherapy company using its CytoSorb® blood purification technology to control severe, deadly inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome.
CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 8,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's websites: http://www.cytosorbents.com and http://www.cytosorb.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.
Please Click to Follow us on Facebook and Twitter
CytoSorbents Medical, Inc
(732) 329-8885 ext. *825
The Ruth Group
Public Relations Contact
The Ruth Group
Source: CytoSorbents Corporation